Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Auto stocks lead among gainers
Mon, 11 Aug 11:30 am

After opening firm, the Indian markets have remained much above the dotted line in the morning trading session. Barring stocks from FMCG and Power sector all the sectoral indices are trading strong.

The BSE-Sensex is trading up 167 points. The NSE-Nifty is trading up 47 points. The BSE Mid Cap index is trading up 0.72% and the BSE Small Cap index is trading up 1.72%. The rupee is trading at 61.55 to the US dollar.

Majority Automobile stocks are trading in strong with Mahindra and Mahindra Ltd (M&M) and TVS motors being the leading gainers in the pack. As per the financial daily, Maruti Suzuki is targeting to sell three million vehicles annually. Reportedly, as per the chairman R. C. Bhargava, company would be at the forefront of the efforts to make India a significant player in the global marketplace. To achieve this target, the company is enhancing its research and development capabilities in order to increase the fuel efficiency and develop eco-friendly models. The company is investing Rs.20 bn at its R&D centre and test course at Rohtak, Haryana, which is Suzuki's first global R&D centre outside Japan. Maruti Suzuki is trading up by 1% at the time of writing.

While stocks from Indian pharma stocks are trading in green with Aurobindo Ltd and JB chemicals being among the leading losers. The stocks of MNC pharma companies are witnessing selling pressures with Sanofi India and Merck Ltd being the leading losers. As per the financial daily, the pharma companies are looking to bring some solution to price controls brought by the authorities. The move comes after the pharma companies lost the petition in Delhi high court to bring stay over the drug price control order. Thus the pharma companies are now looking to have dialogue with the government on the pricing of the drugs. Recently, in July NPPA had brought another 100 drugs under pricing control. Both Indian pharma companies and MNC in particular were expected to get impacted due to this another round of price control proposed by the India regulators. On back of this event, the companies contended the order and filed a petition in the court. On August 1, the Delhi High Court had dismissed a petition filed by the Organization of pharmaceutical producers of India (OPPI) seeking a stay on NPPA's July 10 order of fixing prices. However, the responses from the pricing authority will be given by September 29.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Auto stocks lead among gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.